These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 14688709)

  • 1. Optimal management when unsuspected N2 nodal disease is identified during thoracotomy for lung cancer: cost-effectiveness analysis.
    Ferguson MK
    J Thorac Cardiovasc Surg; 2003 Dec; 126(6):1935-42. PubMed ID: 14688709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer.
    Meyers BF; Haddad F; Siegel BA; Zoole JB; Battafarano RJ; Veeramachaneni N; Cooper JD; Patterson GA
    J Thorac Cardiovasc Surg; 2006 Apr; 131(4):822-9; discussion 822-9. PubMed ID: 16580440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of pulmonary resection and systemic chemotherapy in the management of metastatic soft tissue sarcoma: a combined analysis from the University of Texas M. D. Anderson and Memorial Sloan-Kettering Cancer Centers.
    Porter GA; Cantor SB; Walsh GL; Rusch VW; Leung DH; DeJesus AY; Pollock RE; Brennan MF; Pisters PW
    J Thorac Cardiovasc Surg; 2004 May; 127(5):1366-72. PubMed ID: 15115994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of surgical intervention and stereotactic body radiation therapy for stage I lung cancer in high-risk patients: a decision analysis.
    Puri V; Crabtree TD; Kymes S; Gregory M; Bell J; Bradley JD; Robinson C; Patterson GA; Kreisel D; Krupnick AS; Meyers BF
    J Thorac Cardiovasc Surg; 2012 Feb; 143(2):428-36. PubMed ID: 22169443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival of patients with unsuspected N2 (stage IIIA) nonsmall-cell lung cancer.
    Cerfolio RJ; Bryant AS
    Ann Thorac Surg; 2008 Aug; 86(2):362-6; discussion 366-7. PubMed ID: 18640297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer.
    Shah A; Hahn SM; Stetson RL; Friedberg JS; Pechet TT; Sher DJ
    Cancer; 2013 Sep; 119(17):3123-32. PubMed ID: 23720093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA-IIIB) lung cancer.
    Takeda S; Maeda H; Okada T; Yamaguchi T; Nakagawa M; Yokota S; Sawabata N; Ohta M
    Eur J Cardiothorac Surg; 2006 Jul; 30(1):184-9. PubMed ID: 16730452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of multiple metastatic nodal stations on survival in patients with resectable N1 and N2 nonsmall-cell lung cancer.
    Kang CH; Ra YJ; Kim YT; Jheon SH; Sung SW; Kim JH
    Ann Thorac Surg; 2008 Oct; 86(4):1092-7. PubMed ID: 18805138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolution of treatment outcomes for resected stage IIIA non-small cell lung cancer over 16 years at a single institution.
    Martin LW; Correa AM; Hofstetter W; Hong WK; Komaki R; Putnam JB; Rice DC; Smythe WR; Swisher SG; Vaporciyan AA; Walsh GL; Roth JA
    J Thorac Cardiovasc Surg; 2005 Dec; 130(6):1601-10. PubMed ID: 16308005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer.
    van den Hout WB; Kramer GW; Noordijk EM; Leer JW
    J Natl Cancer Inst; 2006 Dec; 98(24):1786-94. PubMed ID: 17179480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The treatment of patients with stage IIIA non-small cell lung cancer from N2 disease: who returns to the surgical arena and who survives.
    Cerfolio RJ; Maniscalco L; Bryant AS
    Ann Thorac Surg; 2008 Sep; 86(3):912-20; discussion 912-20. PubMed ID: 18721582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.
    Sonett JR; Suntharalingam M; Edelman MJ; Patel AB; Gamliel Z; Doyle A; Hausner P; Krasna M
    Ann Thorac Surg; 2004 Oct; 78(4):1200-5; discussion 1206. PubMed ID: 15464470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotracer-guided thoracoscopic resection is a cost-effective technique for the evaluation of subcentimeter pulmonary nodules.
    Grogan EL; Stukenborg GJ; Nagji AS; Simmons W; Kozower BD; Jones DR; Daniel TM
    Ann Thorac Surg; 2008 Sep; 86(3):934-40; discussion 934-40. PubMed ID: 18721586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.
    van Meerbeeck JP; Kramer GW; Van Schil PE; Legrand C; Smit EF; Schramel F; Tjan-Heijnen VC; Biesma B; Debruyne C; van Zandwijk N; Splinter TA; Giaccone G;
    J Natl Cancer Inst; 2007 Mar; 99(6):442-50. PubMed ID: 17374834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary resection after concurrent chemotherapy and high dose (60Gy) radiation for non-small cell lung cancer is safe and may provide increased survival.
    Cerfolio RJ; Bryant AS; Jones VL; Cerfolio RM
    Eur J Cardiothorac Surg; 2009 Apr; 35(4):718-23; discussion 723. PubMed ID: 19233668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival and risk factors of surgically treated mediastinal invasion T4 non-small cell lung cancer.
    Yang HX; Hou X; Lin P; Rong TH; Yang H; Fu JH
    Ann Thorac Surg; 2009 Aug; 88(2):372-8. PubMed ID: 19632375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of initial operations in non-small cell lung cancer patients with single-level N2 disease.
    Ohta Y; Shimizu Y; Minato H; Matsumoto I; Oda M; Watanabe G
    Ann Thorac Surg; 2006 Feb; 81(2):427-33. PubMed ID: 16427826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone.
    Yovino S; Kwok Y; Krasna M; Bangalore M; Suntharalingam M
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1438-43. PubMed ID: 16029805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis.
    El-Sherif A; Gooding WE; Santos R; Pettiford B; Ferson PF; Fernando HC; Urda SJ; Luketich JD; Landreneau RJ
    Ann Thorac Surg; 2006 Aug; 82(2):408-15; discussion 415-6. PubMed ID: 16863738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of subcarinal station in non-small cell lung cancer with T1-3 N2 disease.
    Iwasaki A; Shirakusa T; Miyoshi T; Hamada T; Enatsu S; Maekawa S; Hiratsuka M
    Thorac Cardiovasc Surg; 2006 Feb; 54(1):42-6. PubMed ID: 16485188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.